These variations expectedly contribute to suppressed levels of nitric oxide and enhanced levels of angiotensin II, and thus vascular constriction, which is a hallmark of HAPE and pulmonary hypertension. The gene discussed is AGT; the disease is pulmonary arterial hypertension.